All holdings
Crispr Therapeutics CRSP
Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them
Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance
Share price change by quarter -13.0% Q3 ’24
-16.2% Q4 ’24
-13.5% Q1 ’25
+42.9% Q2 ’25
+33.2% Q3 ’25
-19.1% Q4 ’25
-9.3% Q1 ’26
+14.7% Q2 ’26
Q3 ’24: -13.0%; Q4 ’24: -16.2%; Q1 ’25: -13.5%; Q2 ’25: +42.9%; Q3 ’25: +33.2%; Q4 ’25: -19.1%; Q1 ’26: -9.3%; Q2 ’26: +14.7% Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.
Managers holding it, by quarter 1 Q4 ’23
1 Q1 ’24
1 Q2 ’24
1 Q3 ’24
1 Q4 ’24
1 Q1 ’25
1 Q2 ’25
1 Q3 ’25
1 Q4 ’25
1 Q1 ’26
1 Q2 ’26
0 Q3 ’26
Q4 ’23: 1; Q1 ’24: 1; Q2 ’24: 1; Q3 ’24: 1; Q4 ’24: 1; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0 Counts the managers on this site whose 13F for that quarter includes Crispr Therapeutics.
Who holds it Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.
Managers holding Crispr Therapeutics Manager Portfolio▼ Value Change Held for Horizon Kinetics 0.0%$510k $510k ▼ Trimmed -4.5%26 qtrs
Download the holders: CSV · JSON · Markdown
Directors buying and selling Open-market trades by directors, officers and 10% holders over the last 12 months. How this works From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Sort by Date (high to low) Date (low to high) Who (Z–A) Who (A–Z) Shares (high to low) Shares (low to high) Value (high to low) Value (low to high) Insider purchases and sales of Crispr Therapeutics Date▼ Who Bought or sold Shares Price Value Filing 19 Oct 2026 Kulkarni SamarthChief Executive Officer ▼ Sold 47,837 $49.78 $2.4m Form 4
About the company Sector Health care · Biological Products, (No Diagnostic Substances) Financial year ends 31 December Shares outstanding 97m at 31 Jul 2026 SEC filings Annual reports and other filings on EDGAR Revenue and profit 2014
$719k 2020
$915m 2021
$1.2m 2022
$371m 2023
$37.3m 2024
$3.5m 2025
2014: not held; 2020: $719k; 2021: $915m; 2022: $1.2m; 2023: $371m; 2024: $37.3m; 2025: $3.5m Crispr Therapeutics revenue and net income by year Year Revenue Net income 2025 $3.5m −$582m 2024 $37.3m −$366m 2023 $371m −$154m 2022 $1.2m −$650m 2021 $915m $378m 2020 $719k −$349m 2014 – −$7.0m
From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.